Editorial
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2011; 17(4): 419-432
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.419
Peginterferon and ribavirin treatment for hepatitis C virus infection
Akihito Tsubota, Kiyotaka Fujise, Yoshihisa Namiki, Norio Tada
Akihito Tsubota, Kiyotaka Fujise, Yoshihisa Namiki, Norio Tada, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan
Author contributions: Tsubota A, Fujise K, Namiki Y and Tada N all generated the ideas and contributed to the writing of this manuscript.
Correspondence to: Akihito Tsubota, MD, PhD, Associate Professor, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan. atsubo@jikei.ac.jp
Telephone: +81-4-71641111 Fax: +81-4-71668638
Received: June 28, 2010
Revised: August 2, 2010
Accepted: August 9, 2010
Published online: January 28, 2011
Abstract

Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.

Keywords: Pegylated interferon α; Ribavirin; Chronic hepatitis C virus infection; Difficult-to-treat patient; Individualized treatment; Response-guided therapy; Specifically targeted antiviral therapy for hepatitis C virus